BioVie to present clinical safety data from ascites Phase 2 trial at AASLD in November
BioVie Inc (NASDAQ:BIVI) has announced that clinical safety data from its Phase 2 open-label study evaluating the efficacy and safety of BIV201,...
Source: proactiveinvestors.com